Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohide Tamura

Showing results (31-40 of 263) with videos related to

Pageof 27
Sort By:
Oncology Letters|August 1, 2012
Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapyToshiaki Takahashi, Nobuyuki Yamamoto, Tomohide Tamura, et al.
Molecular Cancer|April 27, 2013
Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant gliomaYasufumi Katanasaka, Yasuo Kodera, Yuka Kitamura, et al.
Cancer Science|June 11, 2009
Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cellsTomoya Fukui, Yasuo Kodera, Kazuto Nishio, et al.
Biochemical and Biophysical Research Communications|November 12, 2013
Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpointYusuke Nakadate, Yasuo Kodera, Yuka Kitamura, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2005
Translational studies for target-based drugsKazuto Nishio, Tokuzo Arao, Tatsu Shimoyama, et al.
Japanese Journal of Clinical Oncology|November 11, 2006
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumorsYasuhito Fujisaka, Atsushi Horiike, Toshio Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2008
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapyIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Letters|March 12, 2014
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell linesYasufumi Katanasaka, Yasuo Kodera, Mayu Yunokawa, et al.
Cancer Science|July 14, 2007
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathwayKazuko Sakai, Hideyuki Yokote, Kimiko Murakami-Murofushi, et al.
Radiation Oncology (London, England)|June 4, 2009
Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202Naoko Sanuki-Fujimoto, Satoshi Ishikura, Kazushige Hayakawa, et al.
Pageof 27

Showing results (31-40 of 263) with videos related to

Sort By:
Pageof 27
Oncology Letters|August 1, 2012
Pharmacokinetic and pharmacodynamic profiles of subcutaneous administration of continuous erythropoietin receptor activator in lung cancer patients with anemia induced by chemotherapyToshiaki Takahashi, Nobuyuki Yamamoto, Tomohide Tamura, et al.
Molecular Cancer|April 27, 2013
Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant gliomaYasufumi Katanasaka, Yasuo Kodera, Yuka Kitamura, et al.
Cancer Science|June 11, 2009
Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cellsTomoya Fukui, Yasuo Kodera, Kazuto Nishio, et al.
Biochemical and Biophysical Research Communications|November 12, 2013
Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpointYusuke Nakadate, Yasuo Kodera, Yuka Kitamura, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2005
Translational studies for target-based drugsKazuto Nishio, Tokuzo Arao, Tatsu Shimoyama, et al.
Japanese Journal of Clinical Oncology|November 11, 2006
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumorsYasuhito Fujisaka, Atsushi Horiike, Toshio Shimizu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2008
Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapyIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Letters|March 12, 2014
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell linesYasufumi Katanasaka, Yasuo Kodera, Mayu Yunokawa, et al.
Cancer Science|July 14, 2007
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathwayKazuko Sakai, Hideyuki Yokote, Kimiko Murakami-Murofushi, et al.
Radiation Oncology (London, England)|June 4, 2009
Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202Naoko Sanuki-Fujimoto, Satoshi Ishikura, Kazushige Hayakawa, et al.
Pageof 27